Research programme: cannabidiol/tetrahydrocannabinol based therapeutics - Pivot Pharmaceuticals

Drug Profile

Research programme: cannabidiol/tetrahydrocannabinol based therapeutics - Pivot Pharmaceuticals

Alternative Names: PVT-011; PVT-012; PVT-013; PVT-014

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pivot Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Decreased libido; Dysmenorrhoea; Eye disorders; Skin disorders

Most Recent Events

  • 24 Nov 2017 Early research in Decreased libido in Canada (Topical) before November 2017
  • 24 Nov 2017 Early research in Dysmenorrhoea in Canada (Topical) before November 2017
  • 24 Nov 2017 Early research in Eye disorders in Canada (Topical) before November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top